SAN FRANCISCO (MarketWatch) -- AstraZeneca PLC said Monday that results from a one-year study show that patients taking its Symbicort single-inhaler therapy had fewer asthma attacks and required less ...
MADISON, Wis.--(BUSINESS WIRE)--Propeller Health, a leading digital health company dedicated to the management of asthma and COPD, today announced it has received 510(k) clearance from the U.S. Food ...
Melbourne, Australia-based Adherium, a digital health company that focuses in improving medication adherence and patient outcomes, has just received FDA clearance for a new inhaler monitoring device ...
Smart inhaler company Adherium announced last week that it has received 510(k) clearance for over-the-counter sales of its inhaler monitoring device for AstraZeneca’s Symbicort aerosol inhaler, called ...
AstraZeneca, the UK-based maker of popular inhalers like Symbicort and Airsupra, announced Monday it plans to cap costs for patients using its inhalers in the U.S. at $35 per month starting June 1.
In the courtroom fracas over the patents on AstraZeneca’s multibillion-dollar inhaler Symbicort, Viatris and Kindeva Drug Delivery have toppled yet another intellectual property pillar. Still, ...
Starting Saturday, the cost of inhalers will fall for many Americans, as new out-of-pocket price caps go into effect for the asthma medications from AstraZeneca and Boehringer Ingelheim. Following ...
Findings from a trial comparing the real-world effectiveness of asthma inhalers could reshape how children with asthma are treated. In the first randomized controlled trial to investigate the use of a ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results